JG
NKTR icon

Jefferies Group’s Nektar Therapeutics NKTR Stock Holding History

Jefferies Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,800
Closed -$1.03M – 1759
2022
Q1 		$1.03M Buy
12,800
+6,267
+96% +$927K 0.01% 879
2021
Q4 		$1.32M Buy
+6,533
New +$1.42M 0.01% 916
2019
Q3 		– Sell
-14,667
Closed -$7.83M – 2924
2019
Q2 		$7.83M Buy
+14,667
New +$7.35M 0.06% 291
2016
Q2 		– Sell
-3,420
Closed -$705K – 2345
2016
Q1 		$705K Buy
+3,420
New +$657K ﹤0.01% 1287
2015
Q4 		– Sell
-3,107
Closed -$511K – 2466
2015
Q3 		$511K Buy
+3,107
New +$550K ﹤0.01% 1501

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jefferies Group's NKTR Position: Q2 2022 in Review

Jefferies Group sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 6,351 shares — an estimated $401K sold.

Jefferies Group first reported a position in NKTR in Q2 2013 and held it in 15 quarters. The position peaked at $2.93M in Q3 2018. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Jefferies Group reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jefferies Group sold 6,351 Nektar Therapeutics shares in Q2 2022, an estimated $401K.
  • Jefferies Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 15 quarters.
  • Jefferies Group's Nektar Therapeutics position peaked at $2.93M in Q3 2018.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.